Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Amoxicillin/clavulanic acid controlled release - GSK

Next Previous
X
Search
Drug Profile

Amoxicillin/clavulanic acid controlled release - GSK

Alternative Names: Amoxicillin 1000mg/clavulanic acid 62.5mg; Amoxicillin/clavulanic acid modified release; Augmentin SR; Augmentin XR; Extended-release amoxicillin/clavulanic acid; Pharmacokinetically enhanced amoxicillin/clavulanate - GSK

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class 2 ring heterocyclic compounds; Antibacterials; Azetidines; Beta-lactams; Carboxylic acids; Oxazolidinones; Penicillins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute sinusitis; Community-acquired pneumonia

Most Recent Events

  • 27 Jun 2005 Data presented at the 15th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2005) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 03 Nov 2003 Data presented at the 41st Annual Meeting of the Infectious Diseases Society of America (IDSA-2003) have been added to the adverse events and Bacterial Infections therapeutic trials sections
  • 17 Oct 2003 Registered for Acute exacerbations of chronic bronchitis in Belgium (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top